IL161921A0 - 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases - Google Patents

3-Cyanoquinolines as inhibitors of egf-r and her2 kinases

Info

Publication number
IL161921A0
IL161921A0 IL16192102A IL16192102A IL161921A0 IL 161921 A0 IL161921 A0 IL 161921A0 IL 16192102 A IL16192102 A IL 16192102A IL 16192102 A IL16192102 A IL 16192102A IL 161921 A0 IL161921 A0 IL 161921A0
Authority
IL
Israel
Prior art keywords
cyanoquinolines
egf
inhibitors
her2 kinases
her2
Prior art date
Application number
IL16192102A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL161921A0 publication Critical patent/IL161921A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16192102A 2001-11-27 2002-11-26 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases IL161921A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33356801P 2001-11-27 2001-11-27
PCT/US2002/037918 WO2003050090A1 (en) 2001-11-27 2002-11-26 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Publications (1)

Publication Number Publication Date
IL161921A0 true IL161921A0 (en) 2005-11-20

Family

ID=23303345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16192102A IL161921A0 (en) 2001-11-27 2002-11-26 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases

Country Status (24)

Country Link
US (1) US6821988B2 (es)
EP (1) EP1448531B1 (es)
JP (1) JP2005514384A (es)
KR (1) KR20050044599A (es)
CN (1) CN1659145A (es)
AR (1) AR037438A1 (es)
AT (1) ATE370123T1 (es)
AU (1) AU2002359489B2 (es)
BR (1) BR0214485A (es)
CA (1) CA2467573A1 (es)
CO (1) CO5580828A2 (es)
DE (1) DE60221886D1 (es)
EC (1) ECSP045122A (es)
HU (1) HUP0402228A2 (es)
IL (1) IL161921A0 (es)
MX (1) MXPA04004969A (es)
NO (1) NO20042634L (es)
NZ (1) NZ533118A (es)
PL (1) PL370137A1 (es)
RU (1) RU2309150C2 (es)
TW (1) TW200300348A (es)
UA (1) UA77469C2 (es)
WO (1) WO2003050090A1 (es)
ZA (1) ZA200405025B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
BRPI0413255A (pt) * 2003-08-01 2006-10-03 Wyeth Corp uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
AU2003304497B2 (en) * 2003-09-15 2010-06-24 Wyeth Llc Substituted quinolines as protein tyrosine kinase enzyme inhibitors
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
EP2612853A1 (en) * 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
KR20070049655A (ko) 2004-08-13 2007-05-11 제넨테크, 인크. Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US7624279B2 (en) * 2005-06-29 2009-11-24 Lenovo Singapore Pte. Ltd. System and method for secure O.S. boot from password-protected HDD
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
RU2008139079A (ru) * 2006-06-13 2010-07-20 Вайет (Us) Замещенные 3-цианопиридины в качестве ингибиторов протеинкиназы
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
ITMI20082336A1 (it) * 2008-12-29 2010-06-30 Univ Parma Composti inibitori irreversibili di egfr con attivita' antiproliferativa
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN107441058A (zh) 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
KR101562347B1 (ko) * 2010-06-09 2015-10-22 티안진 헤메이 바이오-텍 컴퍼니 리미티드 시아노퀴놀린 유도체
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
US9364479B2 (en) 2010-08-26 2016-06-14 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
CN103304494B (zh) * 2013-06-20 2015-05-27 河北大学 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2016210345A1 (en) 2015-06-25 2016-12-29 The California Institute For Biomedical Research Composition and methods for inhibiting mammalian sterile 20-like kinase 1
WO2017117474A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
US10828305B2 (en) 2016-03-01 2020-11-10 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
ES2962961T3 (es) 2017-07-28 2024-03-22 Yuhan Corp Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
CN110452232A (zh) * 2019-09-17 2019-11-15 北京振东光明药物研究院有限公司 阿法替尼杂质化合物及其制备方法与应用
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
WO2024187321A1 (zh) * 2023-03-10 2024-09-19 甫康（上海）健康科技有限责任公司 含有egfr抑制剂的药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990082463A (ko) * 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
BR9914164A (pt) * 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
EP1117659B1 (en) 1998-09-29 2003-12-03 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
ES2281372T3 (es) * 1999-12-29 2007-10-01 Wyeth Inhibidores de proteina-quinasa triciclicos.
AU2002210714A1 (en) * 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents

Also Published As

Publication number Publication date
PL370137A1 (en) 2005-05-16
AU2002359489B2 (en) 2008-10-30
EP1448531B1 (en) 2007-08-15
ZA200405025B (en) 2006-12-27
RU2309150C2 (ru) 2007-10-27
ECSP045122A (es) 2004-07-23
TW200300348A (en) 2003-06-01
RU2004119414A (ru) 2006-02-27
NO20042634L (no) 2004-06-23
US6821988B2 (en) 2004-11-23
DE60221886D1 (de) 2007-09-27
NZ533118A (en) 2006-07-28
ATE370123T1 (de) 2007-09-15
WO2003050090A1 (en) 2003-06-19
HUP0402228A2 (hu) 2005-02-28
CO5580828A2 (es) 2005-11-30
US20030149056A1 (en) 2003-08-07
EP1448531A1 (en) 2004-08-25
CN1659145A (zh) 2005-08-24
UA77469C2 (en) 2006-12-15
CA2467573A1 (en) 2003-06-19
BR0214485A (pt) 2004-09-14
AU2002359489A1 (en) 2003-06-23
MXPA04004969A (es) 2004-08-11
AR037438A1 (es) 2004-11-10
KR20050044599A (ko) 2005-05-12
JP2005514384A (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
IL161921A0 (en) 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
HK1160859A1 (en) Inhibitors of tyrosine kinases
IL161576A0 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
EP1363702A4 (en) PROCESS FOR INHIBITING KINASES
MXPA03006420A (es) Diaminotiazoles.
PL377825A1 (pl) Diaminotriazole użyteczne jako inhibitory kinaz białkowych
HK1076598A1 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HK1072545A1 (en) Novel inhibitors of kinases
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2003256297A1 (en) Benzimidazoles and benzothiazoles as inhibitors of map kinase
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
EP1372654A4 (en) QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES
IL161852A0 (en) Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase
EP1379242A4 (en) METHOD OF TREATING CANCERS AND APPROPRIATE COMPOSITIONS
PL369742A1 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
MXPA03009257A (es) Derivados de isoxaxol como inhibidores de src y otras proteinas cinasas.
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
MXPA03006423A (es) Naftostirilos.
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
EP1414427A4 (en) KAVALACTONE COMPOSITIONS AND METHODS OF USE
ZA200305379B (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase.
AU2002303336A1 (en) Isoxaxole derivatives as inhibitors of src and other protein kinases
AU2002317319A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
ZA200500492B (en) Novel inhibitors of kinases